Positron emission tomography–computed tomography in paraneoplastic neurologic disorders: systematic analysis and review
A McKeon, M Apiwattanakul, DH Lachance… - Archives of …, 2010 - jamanetwork.com
Objective To evaluate the cancer detection rate of whole-body positron emission
tomography–computed tomography (PET-CT) in a paraneoplastic neurologic context …
tomography–computed tomography (PET-CT) in a paraneoplastic neurologic context …
Factors affecting the precision of lesion sizing with contrast-enhanced spectral mammography
M del Mar Travieso-Aja, P Naranjo-Santana… - Clinical radiology, 2018 - Elsevier
Aim To evaluate the precision of the pre-surgical measurement of the size of breast cancer
by contrast-enhanced spectral mammography (CESM). Material and methods This was a …
by contrast-enhanced spectral mammography (CESM). Material and methods This was a …
Evaluation of a continuous‐time random‐walk diffusion model for the differentiation of malignant and benign breast lesions and its association with Ki‐67 expression
M Du, D Zou, P Gao, Z Yang, Y Hou… - NMR in …, 2023 - Wiley Online Library
The purpose of the current study was to evaluate the performance of a continuous‐time
random‐walk (CTRW) diffusion model for differentiating malignant and benign breast …
random‐walk (CTRW) diffusion model for differentiating malignant and benign breast …
Clinical and morphological factors predictive of occult involvement of the nipple-areola complex in mastectomy specimens
PR Pirozzi, C Rossetti, I Carelli, CA Ruiz… - European Journal of …, 2010 - Elsevier
OBJECTIVE: To evaluate characteristics predictive of nipple-areola complex (NAC)
involvement by the breast tumor. STUDY DESIGN: Cases of infiltrative ductal carcinoma …
involvement by the breast tumor. STUDY DESIGN: Cases of infiltrative ductal carcinoma …
A retrospective study evaluating the impact of preoperative breast MRI on surgical decision-making in young patients (≤ 50 years) with invasive breast cancer
SD Mukherjee, N Hodgson, PJ Lovrics… - Breast cancer: basic …, 2016 - journals.sagepub.com
Introduction Breast magnetic resonance imaging (MRI) is considered a more sensitive
diagnostic test for detecting invasive breast cancer than mammography or breast ultrasound …
diagnostic test for detecting invasive breast cancer than mammography or breast ultrasound …
Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004
M Brown, K Bauer, M Pare - Breast cancer research and treatment, 2010 - Springer
Breast cancer is the most common cancer among women. It is estimated that 7% of women
who have breast cancer will develop a subsequent second independent breast tumor within …
who have breast cancer will develop a subsequent second independent breast tumor within …
Does magnetic resonance imaging accurately predict residual disease in breast cancer?
CCH Stucky, SA McLaughlin, AC Dueck… - The American journal of …, 2009 - Elsevier
BACKGROUND: The accuracy of magnetic resonance imaging (MRI) in identifying residual
disease after breast conservation therapy (BCT) is unclear. METHOD: Review of an …
disease after breast conservation therapy (BCT) is unclear. METHOD: Review of an …
Robust breast quantitative susceptibility mapping in the presence of silicone
C Böhm, JK Stelter, K Weiss, J Meineke… - Magnetic …, 2023 - Wiley Online Library
Purpose To (a) develop a preconditioned water–fat–silicone total field inversion (wfsTFI)
algorithm that directly estimates the susceptibility map from complex multi‐echo data in the …
algorithm that directly estimates the susceptibility map from complex multi‐echo data in the …
Diagnosis of breast cancer in women age 40 and younger: mammography and breast ultrasound
Z Milošević, V Karapandžić-Plešinac… - Acta chirurgica …, 2009 - doiserbia.nb.rs
UDK 618.19-006.04-073 DOI: 10.2298/ACI0904077M rezime oregionalne bolesti (tumor u
dojci sa metastazama u limfnim~ vorovima, klini~ ki stadijum II i III)–u 53, 8% bolesnica, dok …
dojci sa metastazama u limfnim~ vorovima, klini~ ki stadijum II i III)–u 53, 8% bolesnica, dok …
The potency of refined mouse models: implications for clinical trials
R Graeser, U Fiedler, N Esser… - Current Cancer …, 2010 - ingentaconnect.com
Many promising anti-cancer compounds fail in the clinical phase despite extensive testing in
animal models. Reasons for this failure are varied, ranging from inadequate mouse models …
animal models. Reasons for this failure are varied, ranging from inadequate mouse models …